Tsimafeyeu, I <br/><br/>
FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.  [electronic resource] 

 -  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico  Feb 2017 
 - 265-268 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1699-3055 
<br/><br/><label>Standard No.: </label>10.1007/s12094-016-1524-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Biomarkers, Tumor--metabolism<br/>Carcinoma, Papillary--metabolism<br/>Carcinoma, Renal Cell--metabolism<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunoenzyme Techniques<br/>Kidney Neoplasms--metabolism<br/>Male<br/>Middle Aged<br/>Neoplasm Grading<br/>Neoplasm Staging<br/>Prognosis<br/>Receptor, Fibroblast Growth Factor, Type 2--metabolism<br/>Survival Rate